Reproductive factors for ovarian cancer in southern Chinese women by Pasalich, Maria et al.
INTRODUCTION
Ovarian cancer ranks as the seventh most common cause 
of cancer mortality among women [1], accounting for 4.2% 
of cancer deaths [2]. It is the eighth most common cancer 
in women, with approximately 225,000 new cases reported 
worldwide in 2008 [1]. The incidence of ovarian cancer varies 
geographically. The age-standardised rate (per 100,000 
females) is only 3.8 in China, relatively lower than developed 
countries such the USA (8.8) and Australia (7.7) [1]. The major-
ity of ovarian malignancies are epithelial in origin [3] and are 
often diagnosed in the advanced stages of the disease due to 
the subtle and non-specific symptoms [4]. There is currently 
no effective screening method available for the detection of 
this disease [5], which has an overall five-year survival rate of 
approximately 45% [6]. 
Numerous studies have linked reproductive factors with 
ovarian cancer. Long-term oral contraceptive use and higher 
parity are consistently associated with a reduced ovarian 
cancer risk [7-19]. Hysterectomy has been suggested to be 
protective, estimated to confer a 30%-50% risk reduction [20-
23]. The evidence regarding use of hormone replacement 
therapy is somewhat conflicting, with some studies reporting 
a greater risk of ovarian cancer [19,24], and others revealing 
no association [9,12,25]. In contrast, increased ovarian cancer 
risk has been reported for postmenopausal women [13,26,27] 
and having a family history of breast or ovarian cancer [12,28].
The majority of studies examining the relationship between 
reproductive factors and ovarian cancer have been conducted 
in countries with a high incidence of the disease. The aim 
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Objective: To investigate the association between reproductive factors and the risk of ovarian cancer among southern Chinese 
women.
Methods: A hospital-based case-control study was undertaken in Guangzhou, Guangdong Province, between 2006 and 2008. 
A structured questionnaire was used to obtain information on parity, oral contraceptive use and other reproductive factors in 
a sample of 500 incident ovarian cancer patients and 500 controls (mean age, 59 years). Odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated using unconditional logistic regression models.
Results: High parity was inversely associated with ovarian cancer, with an adjusted OR 0.43 (95% CI, 0.30 to 0.62) for women 
who had given birth to 3 or more children compared to women who had given no more than one birth. Ever use of oral 
contraceptives was also protective against ovarian cancer; adjusted OR 0.56 (95% CI, 0.40 to 0.78). No association was found for 
hormone replacement therapy, menopausal status, hysterectomy and family history of ovarian and/or breast cancer.
Conclusion: High parity and oral contraceptive use are associated with a lower risk of ovarian cancer in southern Chinese 
women.
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of this case-control study was to investigate associations 
between ovarian cancer risk and reproductive factors among 
southern Chinese women, a low incidence population.
MATERIALS AND METHODS
This case-control study was undertaken in Guangzhou, the 
capital city of Guangdong Province in Southern China, be-
tween August 2006 and July 2008. Participants were recruited 
from four public hospitals, i.e., the Overseas Hospital (affiliated 
with Jinan University), General Hospital of Guangzhou Military 
Command, Zhujiang Hospital and Second Affiliated Hospital 
of Zhongshan University. Cases were incident patients who 
had been histopathologically diagnosed with an epithelial 
ovarian tumour within the past 12 months. Half of all case 
tumours were classified as serous, and borderline malignancy 
cases were included. Controls were patients who were 
recruited from wards of the departments of physiotherapy, 
respiratory disease, gastroenterology, ophthalmology and 
orthopedics. Subjects were required to be less than 75 years 
of age, and residents of the metropolitan Guangzhou area for 
at least the past ten years.
Potential cases were identified from the daily census of the 
hospitals. To ensure complete ascertainment of cases, all 
hospital medical records and laboratory pathology reports 
were reviewed. Pathological diagnoses were derived from 
the International Histological Classification of Ovarian Tumors 
recommended by the International Federation of Gynecology 
and Obstetrics [29]. Patients were excluded when ovarian 
cancer was histopathologically confirmed to be neither 
the primary nor final diagnosis, or if they reported memory 
problems affecting their recall of past events. Of the total 504 
ovarian cancer cases consecutively recruited from the four 
hospitals, 500 patients consented to participate and were 
capable of being interviewed.
During the same period, 512 eligible controls were identified 
and frequency matched to cases by age (±5 years). The fol-
lowing exclusion criteria applied for the controls: 1) previous 
diagnosis of ovarian cancer or other malignant diseases; 2) 
a history of bilateral oophorectomy; 3) memory problems; 
4) on long-term mobility restriction; in addition to advanced 
age (i.e., exceeding 75 years) and non-residency. Whenever 
more control subjects appeared to be available than could 
be interviewed, a selection of ward and patient identification 
was made using random numbers. After initial screening of 
potential controls using the hospital daily census records, all 
eligible inpatients had their diagnosis confirmed by histopath-
ological reports to avoid misclassification of the case-control 
status. This systematic selection process was implemented 
throughout the recruitment period. Twelve women who did 
not satisfy the eligibility conditions or declined the interview 
were later excluded, resulting in a final sample of 500 controls 
available for analysis. 
1. Interview
An appointment for a 45 minute face-to-face interview 
with each participant was arranged with the assistance of 
nursing staff, to avoid interference with treatment at the ward 
and before being discharged from hospital. All participants 
provided formal consent prior to the interview. They were also 
assured of confidentiality and their right to withdraw without 
prejudice. Participants were interviewed in the presence 
of their next-of-kin whenever possible, to minimize recall 
error. The interviews were conducted in either Mandarin or 
the Cantonese dialect. All participants were blinded to the 
study hypothesis. The project protocol was approved by the 
participating hospitals, the doctors-in-charge of the relevant 
wards, and the Human Research Ethics Committee of Curtin 
University (approval number HR 78/2006). 
2. Measurements
A structured questionnaire used in a previous study in 
Hangzhou, China [27], was administered to obtain demo-
graphic and lifestyle characteristics, including age, weight (kg), 
height (m), location of residence, employment status, educa-
tion level, smoking status, alcohol consumption and marital 
status. Detailed information on reproductive history, hormonal 
status and heredity was obtained. Self-reported data were 
verified against corresponding entries in medical records and 
any discrepancy found was subsequently rectified. 
3. Statistical analysis
The sample characteristics of cases and controls were 
summarised using descriptive statistics. Univariate analysis 
was then undertaken to compare cases and controls in terms 
of reproductive factors. Odds ratios (ORs) and associated 
95% confidence intervals (CIs) from unconditional logistic 
regression models were used to ascertain the association 
between reproductive factors and the risk of ovarian cancer. 
Only women who had at least one live birth were included in 
the multivariate analysis for parity, due to the low number of 
nulliparous women. For ease of analysis, oral contraceptive 
duration (months) was divided into approximate tertiles based 
on the distribution of controls, with the lowest tertile used as 
the reference category.
Tests for linear trend were also conducted for the cor-
responding continuous variables in the logistic regression 
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models to assess the dose-response relationship between 
reproductive factors and the ovarian cancer risk. The following 
established or plausible confounding factors were adjusted 
for in the logistic regression models: age at interview (years), 
smoking status (never, ever), alcohol drinking (no, yes), 
education level (none/primary, secondary, vocational/tertiary) 
and body mass index (5 years ago, kg/m2). In addition, mutual 
adjustment was made for parity (≤1, ≥2), oral contraceptive 
use (never, ever), hormone replacement therapy (no, yes), 
menopausal status (pre, post), hysterectomy (no, yes) and 
family history of ovarian and/or breast cancer (no, yes). All 
statistical analyses were performed using the SPSS ver. 20 (IBM 
Co., Armonk, NY, USA).
RESULTS
The sample characteristics of women with and without ovar-
ian cancer are shown in Table 1. Compared to controls, women 
with ovarian cancer had a significantly higher mean body mass 
index. The two groups appeared to be similar with respect to 
all other demographic and lifestyle factors. Table 2 provides a 
comparison of the reproductive factors by case-control status. 
A significant difference was observed for parity, with one 
third of controls given birth to 3 or more children, compared 
to 20% for cases. Ever use of oral contraceptives also differed 
significantly between groups, with fewer cases ever using oral 
contraceptives.
The logistic regression results for the reproductive factors 
are summarised in Table 3. A strong inverse association was 
evident between parity and ovarian cancer, with a 60% risk 
reduction among women who had given birth to 3 or more 
children, compared to women with parity ≤1 (adjusted OR 
0.43; 95% CI, 0.30 to 0.62). The corresponding dose-response 
relationship was also significant (p<0.001). The adjusted OR of 
ever use of oral contraceptives was 0.56 (95% CI, 0.40 to 0.78), 
however the effect was not significant for oral contraceptive 
duration of usage. Hormone replacement therapy, meno-
Table 1. Characteristics of southern Chinese women with and with out 
ovarian cancer
Variable Cases Controls p-value*
Age at interview (yr) 59.0±5.6 59.7±6.4 0.10
BMI of 5 yr ago (kg/m2) 21.7±2.5 21.1±2.2 <0.01
Location of residence 0.32
    Urban 362 (72.4) 375 (75.0)
    Rural 138 (27.6) 124 (24.8)
Employment status 0.69
    Unemployed/housewife 163 (32.6) 169 (33.8)
    Working 337 (67.4) 331 (66.2)
Education level 0.90
    None/primary 204 (40.8) 197 (39.4)
    Secondary 171 (34.2) 175 (35.0)
    Vocational/tertiary 125 (25.0) 128 (25.6)
Tobacco smoking 0.49
    Never 481 (96.2) 485 (97.0)
    Ever 19 (3.8) 15 (3.0)
Alcohol drinking 0.16
    No 352 (70.4) 372 (74.4)
    Yes 148 (29.6) 128 (25.6)
Marital status 0.83
    Never married 7 (1.4) 8 (1.6)
    Married 449 (89.8) 443 (88.6)
    Widowed/divorced/separated 44 (8.8) 49 (9.8)
Values are presented as mean±SD or number (%).
BMI, body mass index.
*Chi-square or t-test for difference between cases and controls.
Table 2. Comparison of reproductive factors between case and control 
groups
Reproductive factor Cases Controls p-value*
Parity <0.001
    0 7 (1.4) 12 (2.4)
    1 172 (34.4) 145 (29.0)
    2 220 (44.0) 176 (35.2)
    ≥3 101 (20.2) 167 (33.4)
Oral contraceptive use  0.004
    No 417 (83.4) 380 (76.0)
    Yes 83 (16.6) 120 (24.0)
Oral contraceptive duration (mo)† 76.1±63.5 70.4±61.8 0.53
Hormone replacement therapy 1.00
    No 493 (98.6) 493 (98.6)
    Yes 7 (1.4) 7 (1.4)
Menopausal status 0.24
    Pre 28 (5.6) 20 (4.0)
    Post 472 (94.4) 480 (96.0)
Hysterectomy 0.88
    No 478 (95.6) 477 (95.4)
    Yes 22 (4.4) 23 (4.6)
Ovarian and/or breast cancer 
  in first degree relatives
0.29
    No 480 (96.0) 485 (97.0)
    Yes 20 (4.0) 15 (3.0)
Values are presented as number (%) or mean±SD.
*Chi-square or t-test for difference between cases and controls. †Ever 
users of oral contraceptives.
Maria Pasalich, et al.
http://dx.doi.org/10.3802/jgo.2013.24.2.135138 www.ejgo.org
pausal status, hysterectomy and family history of ovarian and/
or breast cancer were not significantly associated with the 
ovarian cancer risk.
DISCUSSION
In this study, we found that ever use of oral contraceptives 
is associated with a reduced risk of ovarian cancer among 
southern Chinese women. This finding aligns with our previ-
ous study in Hangzhou [27] and supports the results of studies 
with women from higher incidence populations [13,18,26]. 
A similar protective effect was reported in a meta-analysis of 
45 cohort and case-control studies from 21 countries, which 
found an overall relative risk of 0.73 (95% CI, 0.70 to 0.76) for 
ever users of oral contraceptives compared to never users [30]. 
A protective effect for oral contraceptive duration was not 
observed in this study. Previous research conducted in China 
similarly reported no association for oral contraceptive dura-
tion [31,32]. However, a recent review found that the estimated 
relative risk of ovarian cancer could decrease by around 20% 
for every 5 years use of hormonal contraception, and around 
50% for 15 years of use [33]. Duration of oral contraceptive use 
among our study population may be insufficient to produce 
a protective effect, as only 32% of ever users consumed oral 
contraceptives for over 5 years. Increasing parity was also in-
versely associated with the ovarian cancer risk, consistent with 
several epidemiological studies [7-9,14,16,17,19] and a pooled 
analysis of 10 case-control studies from the United States [34]. 
The incessant ovulation hypothesis and the gonadotropin 
hypothesis are two well-known theories explaining the pos-
sible biological mechanisms behind ovarian cancer develop-
Table 3. Ovarian cancer risk according to reproductive factors in southern Chinese women 
Reproductive variable Cases, no. (%) Controls, no. (%) Crude OR (95% CI) Adjusted OR (95% CI)* p for trend
Parity <0.001
    ≤1 179 (35.8) 157 (31.4) 1.00 1.00
    2 220 (44.0) 176 (35.2) 1.10 (0.82–1.47) 0.96 (0.71–1.31)
    ≥3 101 (20.2) 167 (33.4) 0.53 (0.38–0.74) 0.43 (0.30–0.62)
Oral contraceptive use 0.001
    No 417 (83.4) 380 (76.0) 1.00 1.00
    Yes 83 (16.6) 120 (24.0) 0.63 (0.46–0.86) 0.56 (0.40–0.78)
Oral contraceptive duration (mo)† 0.586
    ≤36 28 (33.7) 43  (35.8) 1.00 1.00
    37–60 25 (30.1) 43  (35.8) 0.89  (0.45–1.77) 0.92  (0.45–1.90)
    ≥61 30 (36.1) 34  (28.3) 1.36 (0.68–2.69) 1.19 (0.58–2.47)
Hormone replacement therapy 0.929
    No 493 (98.6) 493 (98.6) 1.00 1.00
    Yes 7 (1.4) 7 (1.4) 1.00 (0.35–2.87) 1.05 (0.35–3.21)
Menopausal status 0.943
    Pre 28 (5.6) 20 (4.0) 1.00 1.00
    Post 472 (94.4) 480 (96.0) 0.70 (0.39–1.26) 0.98 (0.49–1.93)
Hysterectomy 0.636
    No 478 (95.6) 477 (95.4) 1.00 1.00
    Yes 22 (4.4) 23 (4.6) 0.96 (0.53–1.74) 0.86 (0.46–1.62)
Family history of ovarian 
  and/or breast cancer 
0.336
    No 480 (96.0) 485 (97.0) 1.00 1.00
    Yes 20 (4.0) 15 (3.0) 1.35 (0.68–2.66) 1.41 (0.70–2.83)
CI, confidence interval; OR, odds ratio. 
*Estimates from logistic regression models include terms for age (yr), smoking status (never, ever), alcohol drinking (no, yes), education (none/
primary, secondary, vocational/tertiary), body mass index (5 yr ago, kg/m2), and mutually adjusted for parity (≤1, ≥2), oral contraceptive use 
(never, ever), hormone replacement therapy (no, yes), menopausal status (pre, post), hysterectomy (no, yes) and family history of ovarian and/
or breast cancer (no, yes). †Ever users of oral contraceptives.
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ment. The former suggests that repeated turnover of surface 
ovarian epithelium occurring in ovulation increases the odds 
of spontaneous genetic mutations and hence increases the 
risk of ovarian cancer [35,36]. In the latter hypothesis, elevated 
gonadotropin levels cause ovarian epithelial cells to become 
trapped within the surrounding connective tissue, which 
may lead to the formation of inclusion cysts [37-39]. Oral 
contraceptive use and higher parity are thought to reduce 
ovarian cancer risk by decreasing gonadotropin levels and 
suppressing ovulation [40]. 
Consideration must be given to the strengths and limitations 
of this study when interpreting the findings. The implementa-
tion of a standardized identification procedure ensured that 
ascertainment of cases was maximized and complete. To 
avoid misclassification of the case-control status, only incident 
patients who had been histopathologically diagnosed with 
ovarian cancer within the past 12 months were recruited, and 
all controls were confirmed. A high response rate (98%) was 
achieved in the recruitment of inpatients through support 
from the medical doctors and nursing staff. All interviews 
followed the same procedure for both case and control 
groups, while recruitment bias was minimized by sampling 
from different hospitals. Despite the low refusal rate, selection 
bias was unavoidable because all participants were voluntary 
and the hospital-based controls were not randomly selected 
from the community. Nevertheless, the four participating 
hospitals serve the entire catchment region so that our 
participants were still representative of the target population. 
Logistic regression analyses included adjustment for potential 
confounding variables such as body mass index. Nevertheless, 
residual confounding may still exist. 
In conclusion, high parity and oral contraceptive use were 
found to reduce ovarian cancer risk in this population of 
southern Chinese women. Because diagnosis of ovarian can-
cer occurs usually in the late stages, the findings are important 
for cancer prevention in this low incidence population.
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